| Outcome Measures: |
Primary: Maximum observed plasma concentration (Cmax) of metformin, 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Days 5, 10, 15 and 20|Time to reach maximum observed plasma concentration (Cmax) of metformin, 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Days 5, 10, 15 and 20|Area under the plasma concentration versus time curve over the dosing interval, at steady state (AUCtau) of metformin, 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Days 5, 10, 15 and 20 | Secondary: Number of participants with adverse events, participants will be followed upon signing informed consent until the follow-up phone call, an expected average of 7 weeks|Maximum observed plasma concentration (Cmax) of ranolazine and metabolites, 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Days 15 and 20|Time to reach maximum observed plasma concentration (Cmax) of ranolazine and metabolites, 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Days 15 and 20|Area under the plasma concentration versus time curve over the dosing interval, at steady state (AUCtau) of ranolazine and metabolites, 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Days 15 and 20
|
